Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker

BACKGROUND: Biomarkers to optimize extended adjuvant endocrine therapy for women with estrogen receptor (ER)–positive breast cancer are limited. The HOXB13/IL17BR (H/I) biomarker predicts recurrence risk in ER-positive, lymph node–negative breast cancer patients. H/I was evaluated in MA.17 trial for...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Sgroi, Dennis C., Carney, Erin, Zarrella, Elizabeth, Steffel, Lauren, Binns, Shemeica N., Finkelstein, Dianne M., Szymonifka, Jackie, Bhan, Atul K., Shepherd, Lois E., Zhang, Yi, Schnabel, Catherine A., Erlander, Mark G., Ingle, James N., Porter, Peggy, Muss, Hyman B., Pritchard, Katherine I., Tu, Dongsheng, Rimm, David L., Goss, Paul E.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2013
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3888138/
https://ncbi.nlm.nih.gov/pubmed/23812955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djt146
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki